<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">hHprCnfJsxTkHK6yCbDvbzr</article-id>
      <article-id pub-id-type="other">00012</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000600012</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200612</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000600012</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial e risco cardiovascular em mulheres com hipertens&#227;o resistente</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Magnanini</surname>
            <given-names>Monica Maria Ferreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nogueira</surname>
            <given-names>Armando da Rocha</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Marilia S&#225;</given-names>
          </name>
          <xref ref-type="aff" rid="aff04"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bloch</surname>
            <given-names>Katia Vergetti</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
      </contrib-group>
      <aff id="aff04">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <institution content-type="orgname">FIOCRUZ</institution>
        <institution content-type="orgdiv1">Programa de Computa&#231;&#227;o Cient&#237;fica </institution>
        <institution content-type="orgdiv2">Escola Nacional de Sa&#250;de P&#250;blica S&#233;rgio Arouca</institution>
        <country country="BR">Brasil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <institution content-type="orgname">Hospital Universit&#225;rio Clementino Fraga Filho</institution>
        <country country="BR">Brasil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal do Rio de Janeiro</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Departamento de Medicina Preventiva</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <institution content-type="orgname">Instituto de Estudos em Sa&#250;de Coletiva</institution>
        <country country="BR">Brasil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>06</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>6</issue>
      <fpage>484</fpage>
      <lpage>489</lpage>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>06</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>13</day>
          <month>08</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>09</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: Poucos estudos exploraram o valor progn&#243;stico da monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial (MAPA) em pacientes hipertensos resistentes, um grupo que apresenta alto risco. OBJETIVO: Investigar o valor progn&#243;stico da press&#227;o arterial (PA) de vig&#237;lia, em mulheres hipertensas resistentes. M&#201;TODOS: Foram acompanhadas por at&#233; 8,9 anos (m&#233;dia 3,9), 382 mulheres hipertensas resistentes com idade entre 24-92 anos, atendidas em uma unidade de hipertens&#227;o de um hospital universit&#225;rio. As pacientes foram classificadas como controladas (PA de consult&#243;rio &gt; 140/90 mmHg e PA de vig&#237;lia&lt;135/85 mmHg) ou n&#227;o-controladas (PA de consult&#243;rio &gt; 140/90 mmHg e PA de vig&#237;lia &gt; 135/85 mmHg). Analisou-se uma combina&#231;&#227;o de mortalidade cardiovascular, cardiopatia isqu&#234;mica, acidente vascular encef&#225;lico e nefropatia. Utilizou-se o modelo proporcional de Cox para estimar o risco de eventos cardiovasculares ajustado para potenciais confundidores. RESULTADOS: A taxa total de eventos foi de 5,0 por 100 mulheres-ano. No grupo de controladas esse valor foi de 3,7 e entre as n&#227;o-controladas, de 5,8, com p=0.06. Os riscos relativos associados ao aumento de 10 mmHg na PA sist&#243;lica, ajustando para idade e tabagismo atual, foram maiores que os associados a aumentos de 5 mmHg na PA diast&#243;lica. Pacientes com descenso noturno&lt;10% tiveram risco para evento cardiovascular maior que os com descenso noturno &gt; 10%, embora essa associa&#231;&#227;o n&#227;o tenha sido estatisticamente significante. A press&#227;o de vig&#237;lia n&#227;o controlada (sim/n&#227;o) foi um forte fator de risco independente, 1,67 (1,00-2,78). CONCLUS&#195;O: O aumento de 67% no risco de evento cardiovascular quando a PA de vig&#237;lia n&#227;o estava controlada &#233; indicador de que o uso da MAPA &#233; essencial na avalia&#231;&#227;o do controle e como guia das decis&#245;es terap&#234;uticas na hipertens&#227;o resistente.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial</kwd>
        <kwd>hipertens&#227;o</kwd>
        <kwd>doen&#231;as cardiovasculares</kwd>
        <kwd>progn&#243;stico</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>20</day>
        <month>07</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> HIPERTENS&#195;O ARTERIAL SIST&#202;MICA</p>
    <p>Monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial e risco cardiovascular em mulheres com hipertens&#227;o resistente</p>
    <p>
      <bold>Monica Maria Ferreira Magnanini<sup>I</sup>; Armando da Rocha Nogueira<sup>II</sup>; Marilia S&#225; Carvalho<sup>IV</sup>; Katia Vergetti Bloch<sup>I, III</sup></bold>
    </p>
    <p><sup>I</sup>Instituto de Estudos em Sa&#250;de Coletiva, Rio de Janeiro, RJ - Brasil </p>
    <p><sup>II</sup>Hospital Universit&#225;rio Clementino Fraga Filho, Rio de Janeiro, RJ - Brasil/ </p>
    <p><sup>III</sup>Departamento de Medicina Preventiva - Faculdade de Medicina &#150; UFRJ, Rio de Janeiro, RJ - Brasil </p>
    <p><sup>IV</sup>Escola Nacional de Sa&#250;de P&#250;blica S&#233;rgio Arouca &#150; Programa de Computa&#231;&#227;o Cient&#237;fica FIOCRUZ, Rio de Janeiro, RJ - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold>Poucos estudos exploraram o valor progn&#243;stico da monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial (MAPA) em pacientes hipertensos resistentes, um grupo que apresenta alto risco. </p>
    <p><bold>OBJETIVO: </bold>Investigar o valor progn&#243;stico da press&#227;o arterial (PA) de vig&#237;lia, em mulheres hipertensas resistentes. </p>
    <p><bold>M&#201;TODOS: </bold>Foram acompanhadas por at&#233; 8,9 anos (m&#233;dia 3,9), 382 mulheres hipertensas resistentes com idade entre 24-92 anos, atendidas em uma unidade de hipertens&#227;o de um hospital universit&#225;rio. As pacientes foram classificadas como controladas (PA de consult&#243;rio <underline>&gt;</underline> 140/90 mmHg e PA de vig&#237;lia&lt;135/85 mmHg) ou n&#227;o-controladas (PA de consult&#243;rio <underline>&gt;</underline> 140/90 mmHg e PA de vig&#237;lia <underline>&gt;</underline> 135/85 mmHg). Analisou-se uma combina&#231;&#227;o de mortalidade cardiovascular, cardiopatia isqu&#234;mica, acidente vascular encef&#225;lico e nefropatia. Utilizou-se o modelo proporcional de Cox para estimar o risco de eventos cardiovasculares ajustado para potenciais confundidores. </p>
    <p><bold>RESULTADOS:</bold> A taxa total de eventos foi de 5,0 por 100 mulheres-ano. No grupo de controladas esse valor foi de 3,7 e entre as n&#227;o-controladas, de 5,8, com p=0.06. Os riscos relativos associados ao aumento de 10 mmHg na PA sist&#243;lica, ajustando para idade e tabagismo atual, foram maiores que os associados a aumentos de 5 mmHg na PA diast&#243;lica. Pacientes com descenso noturno&lt;10% tiveram risco para evento cardiovascular maior que os com descenso noturno &gt; 10%, embora essa associa&#231;&#227;o n&#227;o tenha sido estatisticamente significante. A press&#227;o de vig&#237;lia n&#227;o controlada (sim/n&#227;o) foi um forte fator de risco independente, 1,67 (1,00-2,78). </p>
    <p><bold>CONCLUS&#195;O:</bold> O aumento de 67% no risco de evento cardiovascular quando a PA de vig&#237;lia n&#227;o estava controlada &#233; indicador de que o uso da MAPA &#233; essencial na avalia&#231;&#227;o do controle e como guia das decis&#245;es terap&#234;uticas na hipertens&#227;o resistente.</p>
    <p><bold>Palavras-chave: </bold>Monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial, hipertens&#227;o, doen&#231;as cardiovasculares, progn&#243;stico.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>As doen&#231;as cardiovasculares s&#227;o a principal causa de mortalidade no mundo e um importante fator contribuinte &#233; a dificuldade de controle da press&#227;o arterial (PA). Embora a terapia medicamentosa da hipertens&#227;o seja amplamente utilizada, a propor&#231;&#227;o de pacientes com PA &lt; 140/90 mmHg ap&#243;s o tratamento varia de 6% a 25%<sup>1</sup>. </p>
    <p>Nos Estados Unidos, n&#227;o houve mudan&#231;as significativas nas taxas de controle da hipertens&#227;o para mulheres examinadas no per&#237;odo 1988 - 1994 quando comparados com o per&#237;odo 1999 - 2004, com as taxas permanecendo abaixo de 50%, enquanto 50% dos homens com 60 anos ou mais atingiram o controle da hipertens&#227;o. Uma poss&#237;vel explica&#231;&#227;o para a falta de controle de press&#227;o arterial observada em mulheres seria o fato de que os m&#233;dicos s&#227;o menos inclinados a sugerir medidas preventivas para mulheres do que para homens, j&#225; que eles efetivamente minimizam o risco cardiovascular das mulheres em compara&#231;&#227;o com os homens, uma vez que n&#227;o reconhecem que mais mulheres do que homens morrem anualmente de doen&#231;as cardiovasculares<sup>2</sup>. </p>
    <p>No Brasil, houve um aumento de 500% na popula&#231;&#227;o idosa em 40 anos. Haver&#225; 32 milh&#245;es de idosos por volta do ano 2020. A expectativa de vida tem aumentado, e na grande maioria de pa&#237;ses, o n&#250;mero de mulheres &#233; maior que o de homens na terceira idade. Entretanto, embora as mulheres tenham uma maior expectativa de vida do que os homens, elas vivem proporcionalmente menos anos com boa sa&#250;de<sup>3,4</sup>. </p>
    <p>Evid&#234;ncias indicam que a monitoriza&#231;&#227;o ambulatorial da PA (MAPA) est&#225; mais intimamente relacionada ao dano em &#243;rg&#227;o-alvo do que as mensura&#231;&#245;es feitas no consult&#243;rio<sup>5-9</sup>. Embora alguns estudos tenham explorado o valor progn&#243;stico da MAPA em indiv&#237;duos hipertensos tratados<sup>10-12</sup>, poucos investigaram essa quest&#227;o em pacientes hipertensos resistentes<sup>13</sup>, um grupo de alto risco que desafia a pr&#225;tica cl&#237;nica. O objetivo desse estudo foi avaliar o desfecho cardiovascular em um grupo de mulheres hipertensas resistentes, comparando mulheres com PA ambulatorial de vig&#237;lia controlada com as n&#227;o-controladas. </p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Trata-se de um estudo de coorte, em 382 mulheres encaminhadas ao ambulat&#243;rio de hipertens&#227;o arterial devido a hipertens&#227;o resistente. A exposi&#231;&#227;o foi PA ambulatorial de vig&#237;lia n&#227;o-controlada no in&#237;cio do estudo e o <italic>endpoint</italic> (desfecho) foi qualquer evento cardiovascular. </p>
    <p>Hipertens&#227;o resistente foi definida como uma PA medida no consult&#243;rio persistentemente mais alta que 140/90 mmHg, a despeito de terapia anti-hipertensiva com tr&#234;s ou mais drogas.</p>
    <p>As pacientes assinaram um termo de consentimento informado para participar do estudo. O estudo est&#225; de acordo com a segunda Declara&#231;&#227;o de Helsinki e foi aprovado pelo Comit&#234; de &#201;tica da Institui&#231;&#227;o. </p>
    <p>
      <bold>Avalia&#231;&#227;o cl&#237;nica</bold>
    </p>
    <p>Todas as pacientes foram submetidas a avalia&#231;&#227;o cl&#237;nica, eletrocardiografia, testes laboratoriais de rotina e exame ecocardiogr&#225;fico. Ap&#243;s a otimiza&#231;&#227;o do regime terap&#234;utico, as pacientes foram submetidas &#224; monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial (MAPA). Hipertens&#227;o secund&#225;ria foi um crit&#233;rio de exclus&#227;o. </p>
    <p>A PA de consult&#243;rio foi medida com a paciente na posi&#231;&#227;o sentada, usando um esfigmoman&#244;metro de coluna de merc&#250;rio calibrado, com manguito de tamanho apropriado. Duas medidas de PA foram feitas durante a consulta (com um intervalo de pelo menos 5 minutos) e a segunda foi utilizada. </p>
    <p>Peso, altura e circunfer&#234;ncia da cintura foram medidos em cada paciente; a circunfer&#234;ncia da cintura foi medida em seu menor di&#226;metro entre a borda costal e a crista il&#237;aca. O &#237;ndice de massa corporal (IMC) foi calculado pelo peso em quilogramas dividido pelo quadrado da altura em metros. Os fatores de risco avaliados foram: diabete (duas medidas de glicemia de jejum <underline>&gt;</underline> 6,9 mmol/l ou em tratamento), dislipidemia, tabagismo atual, sobrepeso/obesidade (sobrepeso definido como IMC <underline>&gt;</underline> 25 kg/m<sup>2</sup> e obesidade como IMC <underline>&gt;</underline> 30 kg/m<sup>2</sup>), sedentarismo (sem atividade f&#237;sica regular, pelo menos 30 minutos por dia, na maior parte dos dias da semana).</p>
    <p>O crit&#233;rio da Sociedade Americana de Ecocardiografia para hipertrofia ventricular esquerda (HVE), que considera a hipertrofia como um &#237;ndice de massa ventricular esquerda (IMVE) &gt;104 g/m<sup>2</sup> para mulheres, foi utilizado<sup>14</sup>. A massa ventricular esquerda (MVE) foi calculada de acordo com Devereux<sup>15</sup> e normalizada para a superf&#237;cie corp&#243;rea para obter o IMVE.</p>
    <p>
      <bold>Acompanhamento</bold>
    </p>
    <p>As pacientes foram acompanhadas em ambulat&#243;rios (hipertens&#227;o, cl&#237;nica m&#233;dica, cardiologia e geriatria) do mesmo hospital. As caracter&#237;sticas das pacientes e a ocorr&#234;ncia de eventos cardiovasculares foram registradas durante as visitas de acompanhamento. As pacientes que n&#227;o retornaram ap&#243;s um ano e n&#227;o puderam ser contatadas por telefone foram pesquisadas no banco de dados do Sistema de Informa&#231;&#227;o sobre Mortalidade (SIM). </p>
    <p>Eventos cardiovasculares inclu&#237;ram doen&#231;a coronariana fatal e n&#227;o-fatal (infarto do mioc&#225;rdio, cirurgia de revasculariza&#231;&#227;o ou angioplastia), doen&#231;a cerebrovascular (Acidente Vascular Encef&#225;lico, corroborado por exame f&#237;sico e/ou tomografia computadorizada) e nefropatia hipertensiva (proteinuria &gt;500 mg/24 h e/ou clearance de creatinina &lt;50 ml/minuto e/ou microalbuminuria de 30&#150;299 mg/dia).</p>
    <p>
      <bold>Monitoriza&#231;&#227;o ambulatorial de PA</bold>
    </p>
    <p>A PA ambulatorial foi registrada usando os equipamentos Oscar (<italic>SunTech Medical</italic>) ou DYNAMAPA, ambos foram aprovados pela Sociedade Brit&#226;nica de Hipertens&#227;o<sup>8</sup>. As leituras da PA foram realizadas a cada 10 minutos durante o dia e a cada 20 minutos &#224; noite. Os dados foram considerados adequados quando um m&#237;nimo de 70 registros v&#225;lidos eram obtidos em 24 horas, com pelo menos dois registros por hora durante a noite. As pacientes registraram seus hor&#225;rios de sono, de modo que o per&#237;odo noturno podia ser programado individualmente no <italic>software</italic><sup>16</sup>. Os seguintes par&#226;metros foram avaliados: m&#233;dia de PA de 24 horas, press&#227;o arterial sist&#243;lica (PAS) e diast&#243;lica (PAD) de vig&#237;lia e noturna e press&#227;o arterial diast&#243;lica (DAP); a press&#227;o de pulso (PP) foi calculada como a press&#227;o sist&#243;lica menos a press&#227;o diast&#243;lica. As pacientes foram classificadas como "n&#227;o-dippers" se apresentassem uma redu&#231;&#227;o na PA &lt;10% do dia para a noite, ou como "dippers", se apresentassem uma redu&#231;&#227;o <underline>&gt;</underline> 10%. As mulheres foram classificadas ou como tendo press&#227;o arterial ambulatorial de vig&#237;lia controlada (hipertens&#227;o arterial resistente do jaleco branco), PA no consult&#243;rio <underline>&gt;</underline> 140/90 mmHg e PA ambulatorial de vig&#237;lia &lt;135/85 mmHg, ou como tendo press&#227;o arterial ambulatorial de vig&#237;lia n&#227;o-controlada (hipertens&#227;o resistente verdadeira), PA no consult&#243;rio <underline>&gt;</underline> 140/90 mmHg e press&#227;o arterial ambulatorial de vig&#237;lia <underline>&gt;</underline> 135/85 mmHg<sup>7</sup>.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica </bold>
    </p>
    <p>Os dados foram expressos como m&#233;dias &#177; desvios-padr&#227;o ou porcentagens. As caracter&#237;sticas basais foram comparadas atrav&#233;s do teste de Mann-Whitney para vari&#225;veis cont&#237;nuas e testes Qui-quadrado para vari&#225;veis categ&#243;ricas. Para as participantes que apresentaram eventos m&#250;ltiplos, a an&#225;lise incluiu apenas o primeiro evento. As taxas de eventos foram expressas como o n&#250;mero de eventos por 100-pacientes-ano, calculadas como a raz&#227;o entre o n&#250;mero de eventos observados e n&#250;mero de pacientes-ano expostas at&#233; a ocorr&#234;ncia do desfecho ou a censura. As curvas de sobrevida foram estimadas usando-se o m&#233;todo do produto limite de Kaplan-Meier e foram comparadas usando-se o teste de log-rank. As vari&#225;veis com um valor de <italic>p</italic> menor ou igual a 0,20 foram inclu&#237;das na an&#225;lise multivariada como potenciais confundidoras.</p>
    <p>O efeito independente da press&#227;o de vig&#237;lia n&#227;o-controlada foi testado usando-se modelo de risco proporcional de Cox (hazard). O efeito de confundimento foi avaliado pela mudan&#231;a que cada vari&#225;vel produziu na estimativa pontual, risco relativo (hazard ratio) da vari&#225;vel categ&#243;rica press&#227;o arterial de vig&#237;lia controlada/n&#227;o-controlada. A modifica&#231;&#227;o de efeito foi investigada usando-se o teste de heterogeneidade para um termo de intera&#231;&#227;o inclu&#237;do no modelo. As an&#225;lises foram realizadas usando-se o<italic> software </italic>STATA 9.0 (StataCorp, Texas, EUA). </p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Das 382 pacientes estudadas, 162 (42,4%) foram classificadas como controladas (PA de consult&#243;rio <underline>&gt;</underline> 140/90 mmHg e PA de vig&#237;lia&lt;135/85 mmHg) e 220 (58,6%) como n&#227;o-controladas (PA de consult&#243;rio <underline>&gt;</underline> 140/90 mmHg e PA de vig&#237;lia <underline>&gt;</underline> 135/85 mmHg). As principais caracter&#237;sticas cl&#237;nicas e valores de PA das pacientes em cada grupo s&#227;o mostrados na <xref ref-type="table" rid="tab01">Tabela 1</xref>. O grupo controlado teve maior m&#233;dia de idade e maior frequ&#234;ncia de dislipidemia do que o grupo n&#227;o-controlado, enquanto o IMC e a circunfer&#234;ncia da cintura eram maiores no grupo n&#227;o-controlado. A frequ&#234;ncia de pacientes Afro-descendentes foi um pouco maior no grupo n&#227;o-controlado. Todas as outras caracter&#237;sticas foram similares nos dois grupos. Os par&#226;metros da press&#227;o arterial foram mais altos no grupo n&#227;o-controlado do que no grupo controlado, exceto pela press&#227;o de pulso, que foi mais alta no grupo controlado. </p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gt01.jpg"/></table-wrap>
    <p>Oitenta e oito por cento das pacientes tomavam tr&#234;s ou quatro medicamentos anti-hipertensivos e 12% tomavam mais do que quatro. Todas as pacientes tomavam diur&#233;ticos. As medica&#231;&#245;es mais frequentemente utilizadas foram inibidores da ECA (89,3%), beta-bloqueadores (79,1%) e bloqueadores dos canais de c&#225;lcio (49,0%). Este &#250;ltimo medicamento era mais frequentemente utilizado pelas pacientes controladas do que pelas n&#227;o-controladas. O regime terap&#234;utico mais comumente utilizado em cada grupo &#233; mostrado na <xref ref-type="table" rid="tab01">Tabela 1</xref>. </p>
    <p>Um total de 42 pacientes (11,0%) foram perdidas para acompanhamento, 14,6% do grupo n&#227;o-controlado e 6,2% do grupo controlado, p=0,01.</p>
    <p>Um total de 73 novos eventos cardiovasculares foram registrados em um per&#237;odo m&#233;dio de 3,9 anos, variando de 1 m&#234;s a 8,9 anos, com 1.474 pessoas-ano em risco. Ocorreram 25 eventos cardiovasculares fatais e 48 eventos n&#227;o-fatais. A taxa total de eventos foi mais baixa no grupo controlado do que no grupo n&#227;o-controlado (3,7 <italic>vs.</italic> 5,8 eventos por 100 mulheres-anos; p=0,06). A probabilidade de sobrevida livre de eventos &#233; apresentada na <xref ref-type="fig" rid="fig01">Figura 1</xref>. A compara&#231;&#227;o das curvas de sobrevida entre os grupos mostrou que a sobrevida foi menor no grupo n&#227;o-controlado do que no grupo controlado, embora a diferen&#231;a n&#227;o tenha sido estatisticamente significativa (<italic>log-rank</italic> p= 0,10). N&#227;o foram observadas diferen&#231;as de sobrevida entre grupos &#233;tnicos. </p>
    <fig id="fig01">
      <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gf01.jpg"/></fig>
    <p>Somente idade e tabagismo atual foram considerados confundidores para a associa&#231;&#227;o entre controle da PA de vig&#237;lia e eventos cardiovasculares nessa popula&#231;&#227;o. Os riscos relativos ajustados para idade e tabagismo atual associados com um incremento de 10 mmHg de PA sist&#243;lica e de 5 mmHg de PA diast&#243;lica s&#227;o mostrados na <xref ref-type="table" rid="tab02">Tabela 2</xref>. Os riscos relativos associados com incremento na press&#227;o sist&#243;lica foram maiores que os associados com incrementos na press&#227;o diast&#243;lica. </p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gt02.jpg"/></table-wrap>
    <p>Pacientes "n&#227;o-dippers" apresentaram um risco maior de ocorr&#234;ncia de eventos cardiovasculares do que pacientes "dippers", RR = 1,42 (0,87 &#150; 2,32), principalmente para as pacientes n&#227;o-controladas (RR = 1,70 (0,93 &#150; 3,10)) do que para as controladas (RR = 0,92 (0,40 &#150; 2,15)), embora essas associa&#231;&#245;es n&#227;o tenham apresentado signific&#226;ncia estat&#237;stica. N&#227;o houve intera&#231;&#227;o entre o padr&#227;o "dipper" e o controle da PA (p=0,34). </p>
    <p>A an&#225;lise de regress&#227;o de Cox mostrou que o controle da PA ambulatorial de vig&#237;lia foi um fator de risco independente para novos eventos cardiovasculares (RR = 1,67 (<xref ref-type="table" rid="tab03">Tabela 3</xref>).</p>
    <table-wrap id="tab03">
      <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gt03.jpg"/></table-wrap>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Os resultados desse estudo prospectivo com mulheres hipertensas resistentes mostraram que, ap&#243;s o ajuste para fatores de risco tradicionais, o controle da PA de vig&#237;lia forneceu informa&#231;&#227;o progn&#243;stica adicional em rela&#231;&#227;o a eventos cardiovasculares. As taxas de incid&#234;ncia, bem como as curvas de sobrevida, mostraram um pior perfil de risco para as pacientes n&#227;o-controladas, embora essa an&#225;lise n&#227;o-ajustada n&#227;o tenha mostrado uma diferen&#231;a acentuada. </p>
    <p>O risco relativo ap&#243;s ajuste para a idade e tabagismo atual foi quase 70% maior no grupo com PA de vig&#237;lia mais alta. Embora as pacientes n&#227;o-controladas tivessem IMC maiores e maior circunfer&#234;ncia da cintura, essas caracter&#237;sticas n&#227;o se mostraram associadas ao risco cardiovascular nessa popula&#231;&#227;o, provavelmente por essas medidas serem muito altas em ambos os grupos. A falta de associa&#231;&#227;o entre dislipidemia e risco cardiovascular pode ser devida a um vi&#233;s de sobrevida na popula&#231;&#227;o que come&#231;ou o estudo. As pacientes com dislipidemia estariam sub-representadas no grupo n&#227;o-controlado, por terem morrido antes do estudo. Os agentes bloqueadores de canais de c&#225;lcio foram mais frequentemente utilizados pelas pacientes controladas (mais velhas), mas o uso desse medicamento n&#227;o foi um fator de risco cardiovascular independente. </p>
    <p>Os resultados sugerem que o padr&#227;o "dipper" pode estar associado a um menor risco cardiovascular e essa associa&#231;&#227;o parece ser mais forte em pacientes que j&#225; apresentam um risco mais alto devido ao elevado n&#237;vel de PA. A ocorr&#234;ncia de modifica&#231;&#227;o de efeito &#233; plaus&#237;vel e podemos n&#227;o ter tido o poder para detect&#225;-la. </p>
    <p>Nossos resultados est&#227;o de acordo com outros estudos realizados em popula&#231;&#245;es hipertensas sob tratamento para investigar o impacto progn&#243;stico da PA ambulatorial<sup>10-13</sup>. </p>
    <p>Redon e cols.<sup>13</sup> estudaram 86 pacientes com PAD&gt; 100 mmHg em uso de tr&#234;s ou mais medicamentos anti-hipertensivos, incluindo um diur&#233;tico. Ap&#243;s 49 meses de acompanhamento, o risco de evento cardiovascular foi significativamente mais alto em pacientes que apresentavam uma PA diast&#243;lica de vig&#237;lia basal mais alta (RR = 6,2; IC95% = 1,38-28,1).</p>
    <p>Verdecchia e cols.<sup>10</sup> mostraram que o controle da PA de vig&#237;lia (MAPA) &#233; superior ao controle da PA de consult&#243;rio para prever o desfecho cardiovascular em pacientes hipertensos sob tratamento, recebendo terapia simples, dupla ou m&#250;ltipla. A taxa de eventos foi mais baixa (0,71 eventos/100 pessoas-ano) em pacientes com PA ambulatorial controlada do que em pacientes n&#227;o-controladas (1,87 eventos/100 pessoas-ano), p=0,003. Quando ambos os controles no consult&#243;rio e ambulatorial da PA foram for&#231;ados no mesmo modelo, apenas o controle ambulatorial da PA atingiu signific&#226;ncia estat&#237;stica.</p>
    <p>Clement e cols.<sup>11</sup> usaram como limite normal para PA ambulatorial o ponto de corte de 135 mm Hg da PA sist&#243;lica de 24-h, e n&#227;o da PA de vig&#237;lia, e n&#227;o usaram a PA diast&#243;lica. Eles encontraram um risco maior de ocorr&#234;ncia de eventos cardiovasculares para os pacientes com PA sist&#243;lica m&#233;dia de 24 horas de 135 mm Hg ou mais alta, com risco relativo ajustado (incluindo PA de consult&#243;rio) de 1,74 (IC95%= 1,15-2,48).</p>
    <p>Pierdomenico e cols.<sup>12</sup> relataram que idade, diabetes, eventos pr&#233;vios e hipertens&#227;o resistente verdadeira (PA no consult&#243;rio <underline>&gt;</underline> 140 ou 90 mmHg e PA de vig&#237;lia <underline>&gt;</underline> 135 ou 85 mmHg) resultaram em preditores independentes de desfecho em pacientes caucasianos. O risco relativo do hipertenso verdadeiro em rela&#231;&#227;o ao pseudo-hipertenso resistente (PA no consult&#243;rio <underline>&gt;</underline> 140 ou 90 mmHg e PA de vig&#237;lia &lt; 135 ou 85 mmHg) encontrado foi de 2,33 (IC 95%= 1,14-4,77).</p>
    <p>Verdecchia e cols.<sup>17</sup> estudaram indiv&#237;duos diagnosticados com hipertens&#227;o essencial e descobriram uma associa&#231;&#227;o forte e estatisticamente significativa, independente entre a diminui&#231;&#227;o abrupta da PA noturna e morbidade cardiovascular em mulheres, mas n&#227;o em homens. A associa&#231;&#227;o encontrada por n&#243;s foi mais fraca, especialmente ap&#243;s o ajuste para valores de PA de 24-horas, o que sugere que para esta popula&#231;&#227;o, uma PA m&#233;dia mais alta durante as 24 horas explica parte do risco mais alto nas pacientes "n&#227;o-dippers". </p>
    <p>Hajjar e cols.<sup>18</sup> mostraram que em adultos sem hist&#243;ria de AVC, aqueles com hipertens&#227;o n&#227;o-controlada apresentavam um maior risco de incapacidade do que aqueles com hipertens&#227;o controlada que tinham um risco de incapacidade igual ao de normotensos. Eles descobriram que, comparadas com homens, as mulheres em particular apresentam um risco aumentado de desenvolvimento de incapacidade devido &#224; hipertens&#227;o. Os autores creditaram o aumento da predisposi&#231;&#227;o &#224; incapacidade em mulheres ao fato da hipertens&#227;o ser mais prevalente entre elas.</p>
    <p>Acreditamos que este tenha sido o primeiro estudo a concentrar-se em mulheres hipertensas resistentes. Nossos resultados refor&#231;am a necessidade de uma estrat&#233;gia terap&#234;utica mais agressiva direcionada ao controle da PA neste grupo em particular. Os m&#233;dicos n&#227;o devem minimizar o risco cardiovascular em mulheres, especialmente em uma popula&#231;&#227;o de alto risco, como a estudada aqui. </p>
    <p>O papel da MAPA para subsidiar abordagens terap&#234;uticas foi definitivamente estabelecido e o m&#233;todo deveria ser inclu&#237;do rotineiramente na avalia&#231;&#227;o do controle da PA em pacientes hipertensos resistentes.</p>
    <p>Algumas limita&#231;&#245;es de nosso estudo devem ser destacadas. Ocorreram mais perdas no grupo n&#227;o-controlado do que no grupo controlado. Isso pode ter produzido um risco relativo subestimado; dessa forma acreditamos que as diferen&#231;as poderiam ter sido ainda maiores caso n&#227;o houvessem ocorrido perdas. </p>
    <p>
      <bold>Conclus&#245;es</bold>
    </p>
    <p>Este estudo sugere uma associa&#231;&#227;o entre a PA de vig&#237;lia (MAPA) elevada e risco cardiovascular em mulheres hipertensas resistentes. Sendo assim, para atingir o objetivo de diminuir a morbidade e a mortalidade cardiovasculares nesta popula&#231;&#227;o, as decis&#245;es devem ser baseadas no controle da PA ambulatorial e n&#227;o no controle da PA de consult&#243;rio. </p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi parcialmente financiado por FINEP/Petrobr&#225;s/Cnpq.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de doutorado de Monica Maria Ferreira Magnanini pela Escola Nacional de Sa&#250;de P&#250;blica S&#233;rgio Arouca - FIOCRUZ.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Monica Maria Ferreira Magnanini </p>
        <p> Rua Carolina Santos, 53 casa 13, M&#233;ier </p>
        <p> 20.720-310, Rio de Janeiro, RJ - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="monica@iesc.ufrj.br">monica@iesc.ufrj.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 06/06/2008; revisado recebido em 13/08/2008, aceito em 05/09/2008.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Cuspidi C, Macca G, Sampieri L, Michev I,    Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target    organ damage in refractory hypertension. J Hypertens. 2001; 9: 2063-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>High prevalence of cardiac and extracardiac target organ damage in refractory hypertension</article-title>
          <source>J Hypertens</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2063</fpage>
          <lpage>70</lpage>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cuspidi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Macca</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sampieri</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Michev</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Salerno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fusi</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Ostchega Y, Dillon CF, Hughes JP, Carroll    M, Yoon S. Trends in hypertension prevalence, awareness, treatment, and control    in older U.S. adults: data from the National Health and Nutrition Examination    Survey 1988 to 2004. J Am Geriatr Soc. 2007: 55: 1056-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004</article-title>
          <source>J Am Geriatr Soc</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1056</fpage>
          <lpage>65</lpage>
          <volume>55</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ostchega</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Dillon</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Carroll</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Lima-Costa MF, Veras R. Aging and public health.    Cad Sa&#250;de P&#250;blica. 2003; 19: 700-1.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Aging and public health</article-title>
          <source>Cad Sa&#250;de P&#250;blica</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>700</fpage>
          <lpage>1</lpage>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lima-Costa</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Veras</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Romero DE, Leite IC, Szwarcwald CL. Healthy    life expectancy in Brazil: applying the Sullivan method. Cad Sa&#250;de P&#250;blica.    2005; 21: S7-S18.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Healthy life expectancy in Brazil: applying the Sullivan method</article-title>
          <source>Cad Sa&#250;de P&#250;blica</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>S7</fpage>
          <lpage>S18</lpage>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Romero</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Leite</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Szwarcwald</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Verdecchia P. Prognostic value of ambulatory    blood pressure: current evidence and clinical implications. Hypertension. 2000;    35: 844-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of ambulatory blood pressure: current evidence and clinical implications</article-title>
          <source>Hypertension</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>844</fpage>
          <lpage>51</lpage>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Verdecchia</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Mancia G, Parati G. Ambulatory blood pressure    monitoring and organ damage. Hypertension. 2000; 36: 894-900.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ambulatory blood pressure monitoring and organ damage</article-title>
          <source>Hypertension</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>894</fpage>
          <lpage>900</lpage>
          <volume>36</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mancia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Parati</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Hansen TW, Jeppesen J, Rasmussen S, Ibsen    H, Torp-Pedersen. Ambulatory blood pressure monitoring and risk of cardiovascular    disease: a population based study. Am J Hypertens. 2006; 19: 243-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study</article-title>
          <source>Am J Hypertens</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>243</fpage>
          <lpage>50</lpage>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hansen</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Jeppesen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rasmussen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ibsen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Torp-Pedersen</surname>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Sociedade Brasileira de Cardiologia. Sociedade    Brasileira de Hipertens&#227;o e Sociedade Brasileira de Nefrologia. IV Diretriz    para uso da monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial     II Diretriz para uso da monitoriza&#231;&#227;o residencial da press&#227;o    arterial. Arq Bras Cardiol. 2005; 85 (sup. 2): 1-18.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>IV Diretriz para uso da monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial - II Diretriz para uso da monitoriza&#231;&#227;o residencial da press&#227;o arterial</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1</fpage>
          <lpage>18</lpage>
          <volume>85</volume>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Nobre F, Coelho EB. Tr&#234;s d&#233;cadas    de MAPA  Monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial    de 24 horas: mudan&#231;as de paradigmas no diagn&#243;stico e tratamento    da hipertens&#227;o arterial. Arq Bras Cardiol. 2003; 81 (4): 428-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tr&#234;s d&#233;cadas de MAPA - Monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial de 24 horas: mudan&#231;as de paradigmas no diagn&#243;stico e tratamento da hipertens&#227;o arterial</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>428</fpage>
          <lpage>34</lpage>
          <issue>4</issue>
          <volume>81</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nobre</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Coelho</surname>
              <given-names>EB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Verdecchia P, Reboldi G, Porcellati C, Schillaci    G, Pede S, Bentivoglio M, et al. Risk of cardiovascular disease in relation    to achieved office and ambulatory blood pressure control in treated hypertensive    subjects. J Am Coll Cardiol. 2002; 39: 878-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>878</fpage>
          <lpage>85</lpage>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Verdecchia</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Reboldi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Porcellati</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schillaci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pede</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bentivoglio</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Clement DL, Buyzere ML, Bacquer DA, de Leeuw    PW, Duprez DA, Fayard RH, et al. Prognostic value of ambulatory blood-pressure    recordings in patients with treated hypertension. N Engl J Med. 2003; 348: 2407-15.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2407</fpage>
          <lpage>15</lpage>
          <volume>348</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Clement</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Buyzere</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Bacquer</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>de Leeuw</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Duprez</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Fayard</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Pierdomenico SD, Lapenna D, Di Tommaso R,    Di Carlo S, Esposito AL, Di Mascio R, et al. Cardiovascular risk in patients    receiving double therapy with false and true nonresponder hypertension. Blood    Press Monit. 2006; 11: 303-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular risk in patients receiving double therapy with false and true nonresponder hypertension</article-title>
          <source>Blood Press Monit</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>303</fpage>
          <lpage>7</lpage>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pierdomenico</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Lapenna</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Di Tommaso</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Di Carlo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Esposito</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Di Mascio</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Redon J, Campos C, Narciso ML, Rodicio JL,    Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring    in refractory hypertension: a prospective study. Hypertension. 1998; 31: 712-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study</article-title>
          <source>Hypertension</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>712</fpage>
          <lpage>8</lpage>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Redon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Campos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Narciso</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Rodicio</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Pascual</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ruilope</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Schiller NB, Shah PM, Crawford M, De Maria    A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the    left ventricle by two-dimensional echocardiography. American Society of Echocardiography    Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.    J Am Soc Echocardiogr. 1989; 2: 358-67.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>358</fpage>
          <lpage>67</lpage>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schiller</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Maria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Feigenbaum</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Devereux RB, Alonso DR, Lutas EM, Gottlieb    GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular    hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>450</fpage>
          <lpage>8</lpage>
          <volume>57</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Lutas</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sachs</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Staessen JA, Fagard R, Thijs L, Amery A.    A consensus view on the technique of ambulatory blood pressure monitoring. The    Fourth Consensus Conference on 24-hour Ambulatory Blood Pressure Monitoring.    Hypertension. 1995; 26: 912-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A consensus view on the technique of ambulatory blood pressure monitoring. The Fourth Consensus Conference on 24-hour Ambulatory Blood Pressure Monitoring</article-title>
          <source>Hypertension</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>912</fpage>
          <lpage>8</lpage>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Staessen</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Fagard</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Thijs</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Amery</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Verdecchia P, Pocellati C, Schillaci G, Boergioni    C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure an independent    predictor of prognosis in essential hypertension. Hypertension.1994; 24: 793-801.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ambulatory blood pressure an independent predictor of prognosis in essential hypertension</article-title>
          <source>Hypertension</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>793</fpage>
          <lpage>801</lpage>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Verdecchia</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pocellati</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schillaci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Boergioni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ciucci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Battistelli</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Hajjar I, Lackland DT, Cupples LA, Lipsitz    LA. Association between concurrent and remote blood pressure and disability    in older adults. Hypertension. 2007; 50: 1026-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association between concurrent and remote blood pressure and disability in older adults</article-title>
          <source>Hypertension</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1026</fpage>
          <lpage>32</lpage>
          <volume>50</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hajjar</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lackland</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Cupples</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Lipsitz</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Ambulatory blood pressure monitoring and cardiovascular risk in resistant hypertensive women</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Few studies have explored the prognostic value of ambulatory blood pressure (ABP) in resistant hypertensive patients, a high-risk group. OBJECTIVE: To investigate the prognostic value of uncontrolled daytime ABP in resistant hypertensive women. METHODS: We followed 382 resistant hypertensive women, aged 24-92 years, from a hypertension unit of a university hospital, for up to 8.9 years (mean 3.9). Patients were classified as controlled (office BP&gt;140/90mmHg and daytime ABP &lt;135/85 mmHg) or uncontrolled (office BP&gt;140/90mmHg and daytime ABP &gt;135/85 mmHg). We analyzed a combined endpoint, consisting of cardiovascular mortality, ischemic heart disease, stroke and nephropathy. Cox proportional hazard models were used to estimate the risk for cardiovascular events, adjusting for potential confounders. RESULTS: The total event rate was 5.0 per 100 women-years. In the controlled and uncontrolled groups, the rates were 3.7 vs. 5.8 events respectively, p=0.06. The relative risks adjusted for age and current smoking status associated with a 10 mmHg increment in systolic ABP were greater than the ones associated with a 5 mmHg increment in diastolic ABP. Non-dipper patients had a higher risk for cardiovascular events than dipper patients (RR = 1.42 (0.87 - 2.32)), although this association had no statistical significance. Uncontrolled daytime blood pressure (yes/no) was a stronger independent risk factor, 1.67 (1.00-2.78). CONCLUSIONS: There was a 67% increase in the risk of a cardiovascular event if daytime ambulatory blood pressure was uncontrolled in women with resistant hypertension. Therefore, it is mandatory to use ABP to evaluate control and to guide therapeutic strategies in resistant hypertensive patients.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Blood pressure monitoring, ambulatory</kwd>
        <kwd>hypertension</kwd>
        <kwd>cardiovascular diseases</kwd>
        <kwd>prognosis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="tx-body2">
          <label>
            <bold>Ambulatory blood pressure monitoring and cardiovascular risk in resistant hypertensive women</bold>
          </label>
          <p>
            <bold>Monica Maria Ferreira Magnanini<sup>I</sup>; Armando da Rocha Nogueira<sup>II</sup>; Marilia S&#225; Carvalho<sup>IV</sup>; Katia Vergetti Bloch<sup>I, III</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Instituto de Estudos em Sa&#250;de Coletiva, Rio de Janeiro, RJ - Brazil</p>
      <p><sup>II</sup>Hospital Universit&#225;rio Clementino Fraga Filho, Rio de Janeiro, RJ - Brazil/</p>
      <p><sup>III</sup>Departamento de Medicina Preventiva - Faculdade de Medicina &#150; UFRJ, Rio de Janeiro, RJ - Brazil</p>
      <p><sup>IV</sup>Escola Nacional de Sa&#250;de P&#250;blica S&#233;rgio Arouca &#150; Programa de Computa&#231;&#227;o Cient&#237;fica FIOCRUZ, Rio de Janeiro, RJ - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Few studies have explored the prognostic value of ambulatory blood pressure (ABP) in resistant hypertensive patients, a high-risk group.</p>
      <p><bold>OBJECTIVE:</bold> To investigate the prognostic value of uncontrolled daytime ABP in resistant hypertensive women.</p>
      <p><bold>METHODS:</bold> We followed 382 resistant hypertensive women, aged 24-92 years, from a hypertension unit of a university hospital, for up to 8.9 years (mean 3.9). Patients were classified as controlled (office BP<underline>&gt;</underline>140/90mmHg and daytime ABP &lt;135/85 mmHg) or uncontrolled (office BP<underline>&gt;</underline>140/90mmHg and daytime ABP <underline>&gt;</underline>135/85 mmHg). We analyzed a combined endpoint, consisting of cardiovascular mortality, ischemic heart disease, stroke and nephropathy. Cox proportional hazard models were used to estimate the risk for cardiovascular events, adjusting for potential confounders.</p>
      <p><bold>RESULTS:</bold> The total event rate was 5.0 per 100 women-years. In the controlled and uncontrolled groups, the rates were 3.7 vs. 5.8 events respectively, p=0.06. The relative risks adjusted for age and current smoking status associated with a 10 mmHg increment in systolic ABP were greater than the ones associated with a 5 mmHg increment in diastolic ABP. Non-dipper patients had a higher risk for cardiovascular events than dipper patients (RR = 1.42 (0.87 &#150; 2.32)), although this association had no statistical significance. Uncontrolled daytime blood pressure (yes/no) was a stronger independent risk factor, 1.67 (1.00-2.78).</p>
      <p><bold>CONCLUSIONS:</bold> There was a 67% increase in the risk of a cardiovascular event if daytime ambulatory blood pressure was uncontrolled in women with resistant hypertension. Therefore, it is mandatory to use ABP to evaluate control and to guide therapeutic strategies in resistant hypertensive patients.</p>
      <p><bold>Key words: </bold>Blood pressure monitoring, ambulatory; hypertension; cardiovascular diseases; prognosis.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Cardiovascular diseases are the main cause of mortality all over the world and an important contributing factor is the difficulty in blood pressure (BP) control. Despite the fact that pharmacological therapy of hypertension is widely spread, the proportion of patients with BP lower than 140/90 mmHg after treatment ranges from 6% to 25%<sup>1</sup>. </p>
      <p>In the USA, there were no significant changes in the rates of hypertension control for women between 1988 to 1994 and 1999 to 2004, with the rates remaining under 50%, while 50% of men aged 60 and older achieved hypertension control. Possible explanations for the poor blood pressure control seen in women may be the fact that physicians are less likely to suggest preventative measures for women than men, as they significantly minimize the cardiovascular risk status of women when compared with men, as they are not aware that more women than men die annually of cardiovascular diseases<sup>2</sup>.</p>
      <p>In Brazil, there was a 500% increase in the elderly population in 40 years. There will be 32 millions of elderly subjects by the year 2020. Life expectancy has been rising, and in an overwhelming majority of countries, women outnumber men in later life. However, although females have higher life expectancy than males, they live proportionally fewer years in good health<sup>3,4</sup>. </p>
      <p>Evidence indicates that ambulatory BP (ABP) measurements are more closely related to target organ damage than office BP measurements<sup>5-9</sup>. Although some studies have explored the prognostic value of ABP in treated hypertensive subjects<sup>10-12</sup>, few investigated this issue in resistant hypertensive patients<sup>13</sup>, a high-risk group that challenges clinical practice.</p>
      <p>The aim of this study was to evaluate the cardiovascular outcome in a cohort of resistant hypertensive women, comparing the ones with controlled daytime ABP with the non-controlled ones.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>The present study design is a cohort of 382 women referred to an outpatient hypertension clinic due to resistant hypertension. The exposure was uncontrolled daytime ABP at the entrance of the study and the endpoint was any cardiovascular event.</p>
      <p>Resistant hypertension was defined as office BP persistently higher than 140/90 mmHg in spite of triple or more intensive antihypertensive therapy.</p>
      <p>Patients gave their informed consent. The study was in accordance with the second Declaration of Helsinki and was approved by the Institutional Review Board.</p>
      <p>
        <bold>Clinical evaluation</bold>
      </p>
      <p>All patients underwent clinical evaluation, electrocardiography, routine laboratory tests and echocardiographic examination. After optimization of the therapeutic regimen, patients were submitted to ABP monitoring. Secondary hypertension was an exclusion criterion.</p>
      <p>The physician measured the patient's office blood pressure in the sitting position, using a calibrated mercury sphygmomanometer with an appropriately-sized cuff. Two BP measurements were taken during the visit (at least 5 min apart) and the second one was used. Weight, height, and waist circumference were determined for each subject; waist circumference was measured at the narrowest diameter between the costal margin and the iliac crest. Body mass index (BMI) was calculated by the weight in kilograms divided by the square of the height in meters.</p>
      <p>Risk factors evaluated were: diabetes (two fasting glycemias <underline>&gt;</underline> 6.9 mmol/L or under treatment), dyslipidemia, current smoking status, overweight/obesity (overweight defined as BMI <underline>&gt;</underline>25 kg/m<sup>2</sup> and obesity as BMI<underline>&gt;</underline>30 kg/m<sup>2</sup>), sedentary lifestyle (no regular physical activity at least 30 min per day, on most days of the week). </p>
      <p>The American Society of Echocardiography criteria for left ventricular hypertrophy (LVH), which considers hypertrophy as a left ventricular mass index (LVMI) &gt;104 g/m<sup>2</sup> for women, was used<sup>14</sup>. LV mass was calculated according to Devereux<sup>15</sup> and normalized for body surface area to obtain the LVMI. </p>
      <p>
        <bold>Follow-up</bold>
      </p>
      <p>Patients were followed at the outpatient clinics (Hypertension, Internal Medicine, Cardiology, and Geriatrics) of the same hospital. Patients' characteristics and the occurrence of cardiovascular events were recorded during follow-up visits. Patients that did not return after one year and that could not be contacted by telephone were searched at the Mortality Information System.</p>
      <p>Cardiovascular events included fatal and nonfatal coronary disease (myocardial infarction, bypass surgery or angioplasty), cerebrovascular disease (stroke, corroborated by physical exam and/or CT scans), and hypertensive nephropathy (proteinuria &gt;500 mg/24 h and/or creatinine clearance &lt;50 ml/min and/or microalbuminuria of 30&#150;299 mg/day).</p>
      <p>
        <bold>Ambulatory BP monitoring</bold>
      </p>
      <p>Ambulatory BP was recorded using the Oscar (SunTech Medical) or DYNAMAPA equipments, both of which have been approved by the British Society of Hypertension<sup>8</sup>. A reading was taken every 10 min throughout the day and every 20 min at night. The data were considered adequate when a minimum of 70 valid records were obtained in 24 h, with at least two records per hour during the nighttime. Patients registered their sleep patterns, so that an individual nighttime pattern could be entered into the software for each patient<sup>16</sup>. The following parameters were evaluated: average 24-h, daytime and nighttime systolic BP (SBP) and diastolic BP (DBP); pulse pressure (PP) was calculated as systolic minus diastolic BP. Patients were defined as nondippers if they had a reduction in BP less than 10% from daytime to nighttime, or as dippers, when otherwise. Women were classified either as having controlled daytime ABP (white coat resistant hypertension), office BP<underline>&gt;</underline>140/90mmHg and daytime ABP &lt;135/85mmHg, or as having uncontrolled daytime ABP (true resistant hypertension), office BP <underline>&gt;</underline>140/90mmHg and daytime ABP <underline>&gt;</underline>135/85 mmHg<sup>7</sup>.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Data were expressed as mean &#177; standard deviation or percentage. Baseline characteristics were compared with Mann-Whitney test for continuous variables and &#967;<sup>2</sup> tests for categorical variables. For the participants who experienced multiple events, the analysis included only the first event. Event rates are expressed as the number of events per 100 patient-years based on the ratio of the observed number of events to the total number of patient-years exposure up to the terminating event or censor. Survival curves were estimated using the Kaplan-Meier product-limit method and were compared by the log-rank test. Variables that had a p value less or equal to 0.20 were included in the multivariate analysis as potential confounders. The independent effect of uncontrolled daytime ABP was tested using multivariate Cox proportional-hazard models. The confounding effect was assessed by the change each variable produced in the point estimate and hazard ratio (relative risk) of the categorical variables controlled /uncontrolled daytime ABP. Effect modification was investigated using a heterogeneity test for an interaction term included in the model. Analyses were carried out using STATA 9.0 (StataCorp, Texas, USA). </p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Of the 382 patients analyzed, 162 (42.4%) were classified as presenting controlled daytime ABP, and 220 (58.6%) as presenting uncontrolled daytime ABP. The main clinical characteristics and BP values of the patients in each group are shown in <xref ref-type="table" rid="tab01-body2">Table 1</xref>. The controlled group was older and more dyslipidemic than the uncontrolled group, whereas body mass index and circumference waist were higher in the uncontrolled group. Afro-Brazilian patients were slightly more frequent in the uncontrolled group. All others characteristics were similar between the groups. The blood pressure parameters were higher in the uncontrolled group than in the controlled group, except for the pulse pressure that was higher in the controlled group.</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gt01-en.jpg"/></table-wrap>
      <p>Eighty-eight percent of the patients had been prescribed three or four antihypertensive drugs and twelve percent were prescribed more than four. All patients were taking diuretics. The most frequently used drugs were ACE inhibitors (89.3%), B-blockers (79.1%) and calcium channel blockers (49.0%). The latter was more frequently used by the controlled patients than by the uncontrolled ones. The most frequently used therapeutic regimen in each group is shown in <xref ref-type="table" rid="tab01-body2">Table 1</xref>.</p>
      <p>Forty-two subjects (11.0%) were lost to follow-up, 14.6% from the uncontrolled group and 6.2% from the controlled group, p=0.01.</p>
      <p>A total of 73 new cardiovascular events were recorded during a mean follow-up period of 3.9 years, ranging from 1 month to 8.9 years, with 1,474.0 person-years at risk. There were 25 fatal and 48 non-fatal cardiovascular events. The total event rate per 100 women-years was 5.0. The incidence rate of events was lower for the controlled group than for the uncontrolled one (3.7 <italic>vs.</italic> 5.8 events per 100 women-years; p=0.06). The probability of event-free survival is presented in <xref ref-type="fig" rid="fig01-body2">Figure 1</xref>. The comparison of survival curves among the groups showed that the survival was lower for the uncontrolled than for the controlled group, although the difference was not statistically significant (log-rank p= 0.10). No race/ethnic-based difference in survival was observed.</p>
      <fig id="fig01-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gf01-en.jpg"/></fig>
      <p>Only age and current smoking status were considered confounders for the association between daytime ABP control and cardiovascular events in this population.</p>
      <p>The relative risks adjusted for age and current smoking status associated with a 10 mmHg increment in systolic ABP and with a 5 mmHg increment in diastolic ABP are reported in <xref ref-type="table" rid="tab02-body2">Table 2</xref>. The relative risks associated with increments in systolic BP were greater than the ones associated with increments in diastolic BP.</p>
      <table-wrap id="tab02-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gt02-en.jpg"/></table-wrap>
      <p>Non-dipper patients had a higher risk for cardiovascular events than dipper patients (RR = 1.42 (0.87 &#150; 2.32)), mainly for the uncontrolled patients (RR = 1.70 (0.93 &#150; 3.10)) when compared to the controlled ones (RR = 0.92 (0.40 &#150; 2.15)), although these associations had no statistical significance. There was no interaction between dipper pattern and BP control (p=0.34). </p>
      <p>Cox regression analysis showed that daytime ABP control was an independent risk factor for new cardiovascular events, RR = 1.67 (<xref ref-type="table" rid="tab03-body2">Table 3</xref>). </p>
      <table-wrap id="tab03-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gt03-en.jpg"/></table-wrap>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The results of our prospective study with resistant hypertensive women showed that, after adjustment for traditional risk factors, the daytime ABP control provided additional prognostic information concerning cardiovascular events. </p>
      <p>The incidence rates as well as the survival curve showed a worst risk profile for the uncontrolled patients, although this unadjusted analysis did not show a striking difference. The relative risk after adjustment for age and current smoking status was almost 70% higher in the group with higher daytime BP.</p>
      <p>Although the uncontrolled patients had higher BMI and larger waist circumference, these characteristics were not associated with cardiovascular risk in this population, probably because these measures were very high in both groups.</p>
      <p>The lack of association between dyslipidemia and cardiovascular risk may be due to a survival bias at baseline. Patients with dyslipidemia would be underrepresented in the uncontrolled group, as they would have died earlier. </p>
      <p>Calcium channel blocker agents were more frequently used by the controlled patients (older ones), but this agents were not an independent cardiovascular risk factor.</p>
      <p>Our results suggest that a dipper pattern may be associated with lower cardiovascular risk, and this association seems to be stronger in patients already at a higher risk due to increased BP levels. Effect modification is plausible and we may not have had the power to detect it. </p>
      <p>Our results are in line with other studies carried out in treated hypertensive populations to investigate the prognostic impact of ABP<sup>10-13</sup>. </p>
      <p>Redon <italic>et al</italic><sup>13</sup> studied 86 patients with DBP&gt; 100 mmHg using three or more antihypertensive drugs, including a diuretic. After 49 months of follow-up, the risk of a cardiovascular event was significantly higher for patients who had a higher daytime diastolic BP at baseline (RR = 6.2; 95%CI = 1.38-28.1).</p>
      <p>Verdecchia <italic>et al</italic><sup>10</sup> showed that ABP control (daytime) is superior to office BP control when predicting cardiovascular outcome in treated hypertensive patients receiving single, double or multiple therapy. The event rate was lower (0.71 events/100 person-years) among patients with controlled ABP than among those with uncontrolled ABP (1.87 events/100 person-years), p=0.003. When both office and ABP controls were forced into the same model, only ABP control achieved significance, with an adjusted relative risk of 0.36 (95%CI 0.18-0.70).</p>
      <p>Clement <italic>et al</italic><sup>11 </sup>used a cutoff of 135 mmHg for 24-h systolic BP, and not for daytime BP, as the normal limit for ABP and did not use the diastolic BP. They found a higher risk of cardiovascular events for the patients with mean 24-h systolic BP of 135 mmHg or higher, with an adjusted relative risk (including office BP) of 1.74 (95%CI 1.15-2.48).</p>
      <p>Pierdomenico <italic>et a</italic>l<sup>12</sup> reported that age, diabetes, previous events and true nonresponsive hypertension (office BP <underline>&gt;</underline> 140 or 90 mmHg and daytime BP <underline>&gt;</underline> 135 or 85 mmHg) resulted in independent predictors of outcome in Caucasian patients. The relative risk for true <italic>vs.</italic> false nonresponders (office BP <underline>&gt;</underline> 140 or 90 mm Hg and daytime BP&lt; 135 or 85 mm Hg) found was 2.33 (95%CI 1.14-4.77).</p>
      <p>Verdecchia et al<sup>17</sup> studied subjects diagnosed with essential hypertension and found a strong significant independent association between blunted nocturnal reduction in BP and cardiovascular morbidity in women, but not in men. The association we found was weaker, especially after adjustment for 24-hour BP values, which can suggest that for this population, a higher average BP over the 24 hours explains part of the higher risk in the nondippers.</p>
      <p>Hajar <italic>et al</italic><sup>18</sup> showed that in stroke-free older adults, those with uncontrolled hypertension had an increased risk of incident disability, whereas those with controlled hypertension had a similar risk of incident disability as those without hypertension. They found that, compared with men, women are particularly at an increased risk of developing disability from hypertension. The authors credited the increased predisposition to disability in women to the fact that hypertension is more prevalent among them. </p>
      <p>As far as we are concerned, this is the first study focused on resistant hypertensive women. Our results reinforce the need of a more aggressive therapeutic strategy towards blood pressure control in this particular group. Physicians should not downgrade the cardiovascular risk status of women, especially in a high risk population as the one studied here. The role of ABP monitoring to guide therapeutic approaches has been definitely established and the method should be included in the assessment of BP control in resistant hypertensive patients routinely.</p>
      <p>Some limitations of our study should be pointed out. There were more losses in the non-controlled group than in the controlled group. This may have produced an underestimated relative risk, so we believe that the differences found could be even bigger without the losses. </p>
      <p>
        <bold>Conclusions</bold>
      </p>
      <p>This study suggests an association between elevated daytime ABP and cardiovascular risk in resistant hypertensive women. Therefore, to achieve the goal of decreasing cardiovascular morbidity and mortality in this population, the decisions should be based on the control of ABP and not on the control of office blood pressure. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was partially funded by FINEP/Petrobr&#225;s/Cnpq.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of doctoral submitted by Monica Maria Ferreira Magnanini, from Escola Nacional de Sa&#250;de P&#250;blica S&#233;rgio Arouca - FIOCRUZ.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Monitoreo ambulatorio de la presi&#243;n Arterial y riesgo cardiovascular en mujeres con hipertensi&#243;n resistente</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: Pocos estudios exploraron el valor pron&#243;stico del monitoreo ambulatorio de presi&#243;n arterial (MAPA) en pacientes hipertensos resistentes, un grupo que presenta alto riesgo. OBJETIVO: Investigar el valor pron&#243;stico de la presi&#243;n arterial (PA) diurna, en mujeres hipertensas resistentes. M&#201;TODOS: Se siguieron por hasta 8,9 a&#241;os (promedio 3,9), a 382 mujeres hipertensas resistentes con edad entre 24 y 92 a&#241;os, atendidas en una unidad de hipertensi&#243;n de un hospital universitario. Se clasificaron a las pacientes como controladas (PA de consultorio&gt;140/90 mmHg y PA diurna&lt;135/85 mmHg) o no-controladas (PA de consultorio&gt;140/90 mmHg y PA diurna&gt;135/85 mmHg). Se analiz&#243; una combinaci&#243;n de mortalidad cardiovascular, cardiopat&#237;a isqu&#233;mica, accidente vascular encef&#225;lico y nefropat&#237;a. Se utiliz&#243; el modelo proporcional de Cox para estimarse el riesgo de eventos cardiovasculares ajustado para potenciales confundidores. RESULTADOS: La tasa total de eventos fue de 5,0 por 100 mujeres-a&#241;o. En el grupo de controladas ese valor fue de 3,7 y entre las no-controladas, de 5,8, con p=0.06. Los riesgos relativos asociados al aumento de 10 mmHg en la PA sist&#243;lica, ajustando para edad y tabaquismo actual, fueron mayores que los asociados a aumentos de 5 mmHg en la PA diast&#243;lica. Pacientes con descenso nocturno &lt;10% tuvieron riesgo para evento cardiovascular mayor que los con descenso nocturno &gt;10%, aunque esa asociaci&#243;n no haya sido estad&#237;sticamente significante. La presi&#243;n diurna no controlada (s&#237;/no) fue un fuerte factor de riesgo independiente, 1,67 (1,00-2,78). CONCLUSI&#211;N: El aumento del 67% en el riesgo de evento cardiovascular cuando la PA diurna no estaba controlada es un indicador de que el empleo del MAPA es esencial en la evaluaci&#243;n del control y como gu&#237;a de las decisiones terap&#233;uticas en la hipertensi&#243;n resistente.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Monitoreo ambulatorio de presi&#243;n arterial</kwd>
        <kwd>hipertensi&#243;n</kwd>
        <kwd>enfermedades cardiovasculares</kwd>
        <kwd>pron&#243;stico</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="tx-body3"/>Monitoreo ambulatorio de la presi&#243;n Arterial y riesgo cardiovascular en mujeres con hipertensi&#243;n resistente</p>
      <p>
        <bold>Monica Maria Ferreira Magnanini<sup>I</sup>; Armando da Rocha Nogueira<sup>II</sup>; Marilia S&#225; Carvalho<sup>IV</sup>; Katia Vergetti Bloch<sup>I, III</sup></bold>
      </p>
      <p><sup>I</sup>Instituto de Estudos em Sa&#250;de Coletiva, Rio de Janeiro, RJ - Brasil</p>
      <p><sup>II</sup>Hospital Universit&#225;rio Clementino Fraga Filho, Rio de Janeiro, RJ - Brasil</p>
      <p><sup>III</sup>Departamento de Medicina Preventiva - Faculdade de Medicina - UFRJ, Rio de Janeiro, RJ - Brasil</p>
      <p><sup>IV</sup>Escola Nacional de Sa&#250;de P&#250;blica S&#233;rgio Arouca - Programa de Computa&#231;&#227;o Cient&#237;fica FIOCRUZ, Rio de Janeiro, RJ - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> Pocos estudios exploraron el valor pron&#243;stico del monitoreo ambulatorio de presi&#243;n arterial (MAPA) en pacientes hipertensos resistentes, un grupo que presenta alto riesgo.</p>
      <p><bold>OBJETIVO:</bold> Investigar el valor pron&#243;stico de la presi&#243;n arterial (PA) diurna, en mujeres hipertensas resistentes.</p>
      <p><bold>M&#201;TODOS:</bold> Se siguieron por hasta 8,9 a&#241;os (promedio 3,9), a 382 mujeres hipertensas resistentes con edad entre 24 y 92 a&#241;os, atendidas en una unidad de hipertensi&#243;n de un hospital universitario. Se clasificaron a las pacientes como controladas (PA de consultorio<underline>&gt;</underline>140/90 mmHg y PA diurna&lt;135/85 mmHg) o no-controladas (PA de consultorio<underline>&gt;</underline>140/90 mmHg y PA diurna<underline>&gt;</underline>135/85 mmHg). Se analiz&#243; una combinaci&#243;n de mortalidad cardiovascular, cardiopat&#237;a isqu&#233;mica, accidente vascular encef&#225;lico y nefropat&#237;a. Se utiliz&#243; el modelo proporcional de Cox para estimarse el riesgo de eventos cardiovasculares ajustado para potenciales confundidores.</p>
      <p><bold>RESULTADOS:</bold> La tasa total de eventos fue de 5,0 por 100 mujeres-a&#241;o. En el grupo de controladas ese valor fue de 3,7 y entre las no-controladas, de 5,8, con p=0.06. Los riesgos relativos asociados al aumento de 10 mmHg en la PA sist&#243;lica, ajustando para edad y tabaquismo actual, fueron mayores que los asociados a aumentos de 5 mmHg en la PA diast&#243;lica. Pacientes con descenso nocturno &lt;10% tuvieron riesgo para evento cardiovascular mayor que los con descenso nocturno &gt;10%, aunque esa asociaci&#243;n no haya sido estad&#237;sticamente significante. La presi&#243;n diurna no controlada (s&#237;/no) fue un fuerte factor de riesgo independiente, 1,67 (1,00-2,78).</p>
      <p><bold>CONCLUSI&#211;N:</bold> El aumento del 67% en el riesgo de evento cardiovascular cuando la PA diurna no estaba controlada es un indicador de que el empleo del MAPA es esencial en la evaluaci&#243;n del control y como gu&#237;a de las decisiones terap&#233;uticas en la hipertensi&#243;n resistente.</p>
      <p><bold>Palabras-clave:</bold> Monitoreo ambulatorio de presi&#243;n arterial, hipertensi&#243;n, enfermedades cardiovasculares, pron&#243;stico.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Las enfermedades cardiovasculares son la principal causa de mortalidad en el mundo y un importante factor contribuyente es la dificultad de control de la presi&#243;n arterial (PA). Aunque se utilice ampliamente la terapia medicamentosa de la hipertensi&#243;n, la proporci&#243;n de pacientes con PA &lt; 140/90 mmHg tras el tratamiento var&#237;a del 6% al 25%<sup>1</sup>. </p>
      <p>En los Estados Unidos, no hubo cambios significativos en las tasas de control de la hipertensi&#243;n para mujeres examinadas en el per&#237;odo de 1988 a 1994, cuando comparados con el per&#237;odo de 1999 a 2004, con las tasas abajo del 50%; mientras que el 50% de los varones con 60 a&#241;os o m&#225;s alcanzaron el control de la hipertensi&#243;n. Una posible explicaci&#243;n para la falta de control de presi&#243;n arterial observada en mujeres ser&#237;a el hecho de que los m&#233;dicos son menos inclinados a sugerir medidas preventivas para mujeres que para varones, ya que ellos efectivamente minimizan el riesgo cardiovascular de las mujeres en comparaci&#243;n con los varones, una vez que no reconocen que m&#225;s mujeres que varones mueren anualmente de enfermedades cardiovasculares<sup>2</sup>.</p>
      <p>En el Brasil, hubo un aumento del 500% en la poblaci&#243;n adulta mayor en los &#250;ltimos 40 a&#241;os. Habr&#225; 32 millones de adultos mayores alrededor del a&#241;o 2020. La expectativa de vida ha aumentado, y en la gran mayor&#237;a de los pa&#237;ses, el n&#250;mero de mujeres es mayor que el de varones en la tercera edad. Sin embargo, aunque las mujeres tienen una mayor expectativa de vida que los varones, ellas viven proporcionalmente menos a&#241;os con una buena salud<sup>3,4</sup>.</p>
      <p>Evidencias indican que el monitoreo ambulatorio de la PA (MAPA) est&#225; m&#225;s &#237;ntimamente relacionado al da&#241;o a &#243;rgano-blanco que las mensuraciones hechas en el consult&#243;rio<sup>5-9</sup>. Aunque algunos estudios exploran el valor pron&#243;stico del MAPA en individuos hipertensos tratados<sup>10-12</sup>, pocos han investigado esa cuesti&#243;n en pacientes hipertensos resistentes<sup>13</sup>, un grupo de alto riesgo que desaf&#237;a la pr&#225;ctica cl&#237;nica. El objetivo de ese estudio fue evaluar el desenlace cardiovascular en un grupo de mujeres hipertensas resistentes, comparando mujeres con PA ambulatoria diurna controlada con las no-controladas.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Se trata de un estudio de cohorte, en 382 mujeres referidas al ambulatorio de hipertensi&#243;n arterial debido a la hipertensi&#243;n resistente. La exposici&#243;n fue PA ambulatoria diurna no-controlada al inicio del estudio y el <italic>endpoint</italic> (desenlace) fue cualquier evento cardiovascular. </p>
      <p>Se defini&#243; la hipertensi&#243;n resistente como una PA medida en el consultorio persistentemente m&#225;s alta que 140/90 mmHg, no obstante la terapia antihipertensiva con tres o m&#225;s f&#225;rmacos.</p>
      <p>Las pacientes firmaron un formulario de consentimiento informado para participar en el estudio. El estudio est&#225; de acuerdo con la segunda Declaraci&#243;n de Helsinki y fue aprobado por el Comit&#233; de &#201;tica de la Instituci&#243;n. </p>
      <p>
        <bold>Evaluaci&#243;n cl&#237;nica</bold>
      </p>
      <p>Todas las pacientes fueron sometidas a evaluaci&#243;n cl&#237;nica, electrocardiograf&#237;a, an&#225;lisis laboratoriales de rutina y examen ecocardiogr&#225;fico. Tras la optimizaci&#243;n del r&#233;gimen terap&#233;utico, las pacientes fueron sometidas al monitoreo ambulatorio de presi&#243;n arterial (MAPA). La hipertensi&#243;n secundaria fue un criterio de exclusi&#243;n. </p>
      <p>Se midi&#243; la PA de consultorio con la paciente en la posici&#243;n sentada, con el empelo de un esfigmoman&#243;metro de columna de mercurio calibrado, con manguito de tama&#241;o apropiado. Durante la consulta, se llevaron a cabo dos mediciones de la PA (con un intervalo de al menos 5 minutos), y se utiliz&#243; la segunda. </p>
      <p>El peso, la altura y la circunferencia de la cintura se midieron en cada paciente; la circunferencia de la cintura se midi&#243; en su menor di&#225;metro entre el borde costal y la cresta il&#237;aca. Se calcul&#243; el &#237;ndice de masa corporal (IMC) con base en el peso en kilogramos dividido por el cuadrado de la altura en metros. Los factores de riesgo evaluados fueron: diabetes (dos medidas de glucemia de ayuno <underline>&gt;</underline> 6,9 mmol/l o en tratamiento), dislipidemia, tabaquismo actual, sobrepeso/obesidad (sobrepeso definido como IMC <underline>&gt;</underline>25 kg/m<sup>2</sup> y obesidad como IMC <underline>&gt;</underline>30 kg/m<sup>2</sup>), sedentarismo (sin actividad f&#237;sica regular, 30 minutos por d&#237;a como m&#237;nimo, en la mayor parte de los d&#237;as de la semana).</p>
      <p>Se emple&#243; el criterio de la Sociedad Americana de Ecocardiograf&#237;a para hipertrofia ventricular izquierda (HVI), que considera la hipertrofia como un &#237;ndice de masa ventricular izquierda (IMVI) &gt;104 g/m<sup>2</sup> para mujeres<sup>14</sup>. La masa ventricular izquierda (MVI) se calcul&#243; seg&#250;n el Devereux<sup>15</sup> y se la normaliz&#243; para la superficie corp&#243;rea para obtenerse el IMVI.</p>
      <p>
        <bold>Seguimiento</bold>
      </p>
      <p>Las pacientes se siguieron en ambulatorios (hipertensi&#243;n, cl&#237;nica m&#233;dica, cardiolog&#237;a y geriatr&#237;a) del mismo hospital. Las caracter&#237;sticas de las pacientes y la ocurrencia de eventos cardiovasculares fueron registradas durante las visitas de seguimiento. Las pacientes que no retornaron tras un a&#241;o y no pudieron ser contactadas por tel&#233;fono se les investigaron en el banco de datos del Sistema de Informaci&#243;n sobre Mortalidad (SIM). </p>
      <p>Eventos cardiovasculares incluyeron enfermedad coronaria fatal y no-fatal (infarto de miocardio, cirug&#237;a de revascularizaci&#243;n o angioplastia), enfermedad cerebrovascular (accidente vascular encef&#225;lico, corroborado por examen f&#237;sico y/o tomograf&#237;a computarizada) y nefropat&#237;a hipertensiva (proteinuria &gt;500 mg/24 h y/o clearance de creatinina &lt;50 ml/minuto y/o microalbuminuria de 30-299 mg/d&#237;a).</p>
      <p>
        <bold>Monitoreo ambulatorio de PA</bold>
      </p>
      <p>Se registr&#243; la PA ambulatoria con el empleo de equipos Oscar (<italic>SunTech Medical</italic>) o DYNAMAPA, y ambos fueron aprobados por la Sociedad Brit&#225;nica de Hipertensi&#243;n<sup>8</sup>. Las lecturas de la PA se llevaron a cabo a cada 10 minutos durante el d&#237;a, y a cada 20 minutos por la noche. Se consideraron los datos como adecuados cuando se obten&#237;a un m&#237;nimo de 70 registros v&#225;lidos en 24 horas, con al menos dos registros por hora durante la noche. Las pacientes registraron sus horarios de sue&#241;o, de modo que se pod&#237;a programar el per&#237;odo nocturno individualmente en el <italic>software</italic><sup>16</sup>. Se evaluaron los par&#225;metros que siguen a continuaci&#243;n: promedio de PA de 24 horas, presi&#243;n arterial sist&#243;lica (PAS) y diast&#243;lica (PAD) diurna y nocturna y presi&#243;n arterial diast&#243;lica (DAP); la presi&#243;n de pulso (PP) se calcul&#243; como la presi&#243;n sist&#243;lica menos la presi&#243;n diast&#243;lica. Las pacientes se clasificaron como no-dippers si presentaran una reducci&#243;n en la PA &lt;10% del d&#237;a para la noche, o como dippers, se presentaran una reducci&#243;n <underline>&gt;</underline>10%. Se clasificaron las mujeres como con presi&#243;n arterial ambulatoria diurna controlada (hipertensi&#243;n arterial resistente de bata blanca), PA en el consultorio <underline>&gt;</underline>140/90mmHg y PA ambulatoria diurna &lt;135/85mmHg, o con presi&#243;n arterial ambulatoria diurna no-controlada (hipertensi&#243;n resistente verdadera), PA en el consultorio <underline>&gt;</underline>140/90mmHg y presi&#243;n arterial ambulatoria diurna <underline>&gt;</underline>135/85 mmHg<sup>7</sup>.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Los dados fueron expresados como promedios &#177; desviaciones-est&#225;ndar o porcentajes. Se compararon las caracter&#237;sticas basales mediante la prueba de Mann-Whitney para variables continuas y pruebas Chi-cuadrado para variables categ&#243;ricas. Para las participantes que presentaron eventos m&#250;ltiples, el an&#225;lisis incluy&#243; solamente el primer evento. Las tasas de eventos estaban expresadas como el n&#250;mero de eventos por 100-pacientes-a&#241;o, calculadas como la raz&#243;n entre el n&#250;mero de eventos observados, y el n&#250;mero de pacientes-a&#241;o expuestas hasta la ocurrencia del desenlace o la censura. Las curvas de sobrevida se estimaron con el empleo del m&#233;todo del producto l&#237;mite de Kaplan-Meier y se las compararon con el empleo del test de log-rank. Las variables con un valor de <italic>p</italic> menor o igual a 0,20 se incluyeron en el an&#225;lisis multivariado como potenciales confundidoras.</p>
      <p>Se prob&#243; el efecto independiente de la presi&#243;n diurna no-controlada con la utilizaci&#243;n del modelo de riesgo proporcional de Cox (hazard). Se evalu&#243; el efecto de confundimiento con base en el cambio que cada variable produzco en la estimativa puntual, riesgo relativo (hazard ratio) de la variable categ&#243;rica presi&#243;n arterial diurna controlada/no-controlada. Se investig&#243; la modificaci&#243;n del efecto con el empleo del test de heterogeneidad para un t&#233;rmino de interacci&#243;n incluido en el modelo. Se realizaron los an&#225;lisis mediante el uso del <italic>software</italic> STATA 9.0 (StataCorp, Texas, EUA).</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>De las 382 pacientes estudiadas, a 162 (42,4%) se clasificaron como controladas (PA de consultorio<underline>&gt;</underline>140/90 mmHg y PA diurna&lt;135/85 mmHg) y a 220 (58,6%) como no-controladas (PA de consultorio<underline>&gt;</underline>140/90 mmHg y PA diurna<underline>&gt;</underline>135/85 mmHg). Las principales caracter&#237;sticas cl&#237;nicas y valores de PA de las pacientes en cada grupo est&#225;n detallados en la <xref ref-type="table" rid="tab01-body3">Tabla 1</xref>. El grupo controlado tuvo mayor promedio de edad y mayor frecuencia de dislipidemia que el grupo no-controlado, mientras que el IMC y la circunferencia de la cintura eran mayores en el grupo no-controlado. La frecuencia de pacientes afrodescendientes fue un poco mayor en el grupo no-controlado. Todas las otras caracter&#237;sticas se mostraron semejantes en los grupos. Los par&#225;metros de la presi&#243;n arterial fueron m&#225;s altos en el grupo no-controlado que en el grupo controlado, excepto por la presi&#243;n de pulso, que fue m&#225;s alta en el grupo controlado. </p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gt01-es.jpg"/></table-wrap>
      <p>El 88% de las pacientes tomaban tres o cuatro medicamentos antihipertensivos y el 12% tomaban m&#225;s que cuatro. Todas las pacientes tomaban diur&#233;ticos. Las medicaciones m&#225;s frecuentemente utilizadas fueron inhibidores de la ECA (89,3%), betabloqueantes (79,1%) y bloqueantes de los canales de calcio (49,0%). Este &#250;ltimo medicamento era m&#225;s frecuentemente utilizado por las pacientes controladas que por las no-controladas. El r&#233;gimen terap&#233;utico m&#225;s com&#250;nmente utilizado en cada grupo est&#225; detallado en la <xref ref-type="table" rid="tab01-body3">Tabla 1</xref>. </p>
      <p>Un total de 42 pacientes (11,0%) se perdieron para seguimiento, un 14,6% del grupo no-controlado y un 6,2% del grupo controlado, p=0,01.</p>
      <p>Un total de 73 nuevos eventos cardiovasculares se registraron en un per&#237;odo promedio de 3,9 a&#241;os, variando de 1 mes a 8,9 a&#241;os, con 1.474 personas-a&#241;o en riesgo. Ocurrieron 25 eventos cardiovasculares fatales y 48 eventos no-fatales. La tasa total de eventos fue m&#225;s baja en el grupo controlado que en el grupo no-controlado (3,7 <italic>vs</italic> 5,8 eventos por 100 mujeres-a&#241;os; p=0,06). La probabilidad de sobrevida libre de eventos est&#225; presentada en la <xref ref-type="fig" rid="fig01-body3">Figura 1</xref>. La comparaci&#243;n de las curvas de sobrevida entre los grupos mostr&#243; que la sobrevida fue menor en el grupo no-controlado que en el grupo controlado, aunque la diferencia no es estad&#237;sticamente significativa (log-rank p= 0,10). No se observaron diferencias de sobrevida entre grupos &#233;tnicos.</p>
      <fig id="fig01-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gf01-es.jpg"/></fig>
      <p>Solamente edad y tabaquismo actual se consideraron como confundidores para la asociaci&#243;n entre control de la PA diurna y eventos cardiovasculares en esa poblaci&#243;n. Los riesgos relativos ajustados para edad y tabaquismo actual asociados a un incremento de 10 mmHg de PA sist&#243;lica y de 5 mmHg de PA diast&#243;lica est&#225;n detallados en la <xref ref-type="table" rid="tab02-body3">Tabla 2</xref>. Los riesgos relativos asociados con incremento en la presi&#243;n sist&#243;lica fueron mayores que los asociados con incrementos en la presi&#243;n diast&#243;lica.</p>
      <table-wrap id="tab02-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gt02-es.jpg"/></table-wrap>
      <p>Pacientes no-dippers presentaron un riesgo mayor de ocurrencia de eventos cardiovasculares que pacientes dippers, RR = 1,42 (0,87 - 2,32), principalmente para las pacientes no-controladas (RR = 1,70 (0,93 - 3,10)) que para las controladas (RR = 0,92 (0,40 - 2,15)), aunque esas asociaciones no presenten significancia estad&#237;stica. No hubo interacci&#243;n entre el est&#225;ndar dipper y el control de la PA (p=0,34). </p>
      <p>El an&#225;lisis de regresi&#243;n de Cox mostr&#243; que el control de la PA ambulatoria diurna fue un factor de riesgo independiente para nuevos eventos cardiovasculares (RR = 1,67 (<xref ref-type="table" rid="tab03-body3">Tabla 3</xref>).</p>
      <table-wrap id="tab03-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0484-00012-gt03-es.jpg"/></table-wrap>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Los resultados de ese estudio prospectivo con mujeres hipertensas resistentes mostraron que, tras el ajuste para factores de riesgo tradicionales, el control de la PA diurna suministr&#243; informaci&#243;n pron&#243;stica adicional con relaci&#243;n a eventos cardiovasculares. Las tasas de incidencia, as&#237; como las curvas de sobrevida, mostraron un peor perfil de riesgo para las pacientes no-controladas, aunque ese an&#225;lisis no-ajustado no haya mostrado una diferencia acentuada. </p>
      <p>El riesgo relativo tras ajuste para la edad y tabaquismo actual fue casi 70% mayor en el grupo con PA diurna m&#225;s alta. Aunque las pacientes no-controladas tuvieran IMC mayores y mayor circunferencia de la cintura, esas caracter&#237;sticas no se mostraron asociadas al riesgo cardiovascular en esa poblaci&#243;n, probablemente por el alto grado de las mediciones en ambos grupos. La falta de asociaci&#243;n entre dislipidemia y riesgo cardiovascular puede ser debida a un sesgo de sobrevida en la poblaci&#243;n que empez&#243; el estudio. Las pacientes con dislipidemia estar&#237;an subrepresentadas en el grupo no-controlado, por haber muerto antes de la realizaci&#243;n del estudio. Los agentes bloqueantes de canales de calcio fueron m&#225;s frecuentemente utilizados por las pacientes controladas (m&#225;s viejas), pero el uso de ese medicamento no fue un factor de riesgo cardiovascular independiente. </p>
      <p>Los resultados sugieren que el est&#225;ndar dipper puede estar asociado a un menor riesgo cardiovascular y esa asociaci&#243;n parece ser m&#225;s fuerte en pacientes que ya presentan un riesgo m&#225;s alto debido al elevado nivel de PA. La ocurrencia de modificaci&#243;n de efecto es plausible y pudimos no haber tenido el poder suficiente para detectarla.</p>
      <p>Nuestros resultados est&#225;n de acuerdo con otros estudios realizados en poblaciones hipertensas bajo tratamiento para investigar el impacto pron&#243;stico de la PA ambulatoria<sup>10-13</sup>.</p>
      <p>Redon et al<sup>13</sup> estudiaron a 86 pacientes con PAD&gt; 100 mmHg en uso de tres o m&#225;s medicamentos antihipertensivos, incluyendo un diur&#233;tico. Tras 49 meses de seguimiento, el riesgo de evento cardiovascular fue significativamente m&#225;s alto en pacientes que presentaban una PA diast&#243;lica diurna basal m&#225;s alta (RR = 6,2; IC95% = 1,38-28,1).</p>
      <p>Verdecchia et al<sup>10</sup> mostraron que el control de la PA diurna (MAPA) es superior al control de la PA de consultorio para prever el desenlace cardiovascular en pacientes hipertensos bajo tratamiento, recibiendo terapia simple, doble o m&#250;ltiple. La tasa de eventos fue m&#225;s baja (0,71 eventos/100 personas-a&#241;o) en pacientes con PA ambulatoria controlada que en pacientes no-controladas (1,87 eventos/100 personas-a&#241;o), p=0,003. Al forzarse ambos controles de la PA, el consultorio y el ambulatorio, en el mismo modelo, s&#243;lo el control ambulatorio de la PA alcanz&#243; significancia estad&#237;stica.</p>
      <p>Clement et al<sup>11</sup> usaron como l&#237;mite normal para PA ambulatoria el punto de corte de 135 mm Hg de la PA sist&#243;lica de 24h, y no de la PA diurna, y no usaron la PA diast&#243;lica. Ellos encontraron un riesgo mayor de ocurrencia de eventos cardiovasculares para los pacientes con PA sist&#243;lica promedio de 24 horas de 135 mm Hg o m&#225;s alta, con riesgo relativo ajustado (incluyendo PA de consultorio) de 1,74 (IC95%= 1,15-2,48).</p>
      <p>Pierdomenico et al<sup>12</sup> relataron que edad, diabetes, eventos previos y hipertensi&#243;n resistente verdadera (PA en el consultorio <underline>&gt;</underline> 140 &#243; 90 mmHg y PA diurna <underline>&gt;</underline> 135 &#243; 85 mmHg) resultaron en predictores independientes de desenlace en pacientes caucasianos. El riesgo relativo del hipertenso verdadero con relaci&#243;n al pseudo hipertenso resistente (PA en el consultorio <underline>&gt;</underline> 140 &#243; 90 mmHg y PA diurna &lt; 135 &#243; 85 mmHg) encontrado fue de 2,33 (IC95%= 1,14-4,77).</p>
      <p>Verdecchia et al<sup>17</sup> estudiaron a individuos diagnosticados con hipertensi&#243;n esencial y descubrieron una asociaci&#243;n fuerte y estad&#237;sticamente significativa, independiente entre la disminuci&#243;n abrupta de la PA nocturna y morbilidad cardiovascular en mujeres, pero no en varones. La asociaci&#243;n que encontramos fue m&#225;s d&#233;bil, espec&#237;ficamente tras el ajuste para valores de PA de 24-horas, lo que sugiere que para esta poblaci&#243;n, una PA promedio m&#225;s alta durante las 24 horas explica parte del riesgo m&#225;s alto en las pacientes no-dippers. </p>
      <p>Hajjar et al<sup>18</sup> mostraron que en adultos sin historia de ACV, aquellos con hipertensi&#243;n no-controlada presentaban un mayor riesgo de incapacidad que aquellos con hipertensi&#243;n controlada que ten&#237;an un riesgo de incapacidad igual al de normotensos. Ellos descubrieron que, comparadas con varones, las mujeres en particular presentan un riesgo aumentado de desarrollo de incapacidad debido a la hipertensi&#243;n. Los autores acreditaron el aumento de la predisposici&#243;n a la incapacidad en mujeres al hecho de la hipertensi&#243;n ser m&#225;s prevalente entre ellas.</p>
      <p>Creemos que este fue el primer estudio a concentrarse en mujeres hipertensas resistentes. Nuestros resultados refuerzan la necesidad de una estrategia terap&#233;utica m&#225;s agresiva dirigida al control de la PA en este grupo en particular. Los m&#233;dicos no deben minimizar el riesgo cardiovascular en mujeres, espec&#237;ficamente en una poblaci&#243;n de alto riesgo, como la estudiada aqu&#237;. </p>
      <p>El rol del MAPA para subsidiar abordajes terap&#233;uticos fue definitivamente establecido y el m&#233;todo se deber&#237;a incluir rutinariamente en la evaluaci&#243;n del control de la PA en pacientes hipertensos resistentes.</p>
      <p>Debemos se&#241;alar aqu&#237; algunas limitaciones de nuestro estudio. Ocurrieron m&#225;s p&#233;rdidas en el grupo no-controlado que en el grupo controlado. Eso puede tener producido un riesgo relativo subestimado; de esa forma, creemos que las diferencias podr&#237;an haber sido todav&#237;a mayores caso no hubieran ocurrido p&#233;rdidas.</p>
      <p>
        <bold>Conclusiones</bold>
      </p>
      <p>Este estudio sugiere una asociaci&#243;n entre la PA diurna (MAPA) elevada y el riesgo cardiovascular en mujeres hipertensas resistentes. As&#237;, para alcanzar el objetivo de disminuir la morbilidad y la mortalidad cardiovasculares en esta poblaci&#243;n, las decisiones deben estar basadas en el control de la PA ambulatoria y no en el control de la PA de consultorio. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio fue parcialmente financiado por FINEP/Petrobras/CNPQ.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de doctorado de Monica Maria Ferreira Magnanini, por la Escuela Nacional de Salud P&#250;blica S&#233;rgio Arouca - FIOCRUZ.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
